EBSEmergent BioSolutions Inc.
Is the business good?
Margins widening. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Operating margin has widened over the past few years, the business is getting more profitable per dollar of sales.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is EBS?
Emergent BioSolutions Inc. earns −6.7% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
Return on invested capital · cost of capital 9.0% · 16 points below what the capital costs: growth destroys value
- Share count, year on year
- −4.8%
Share count, year on year · bought back, each share owns more of the company
| Year | Operating margin |
|---|---|
| FY2020 | 28% |
| FY2021 | 19% |
| FY2022 | −15% |
| FY2023 | −69% |
| FY2024 | −10% |
| FY2025 | 13% |
Details›
- Free cash flow, trailing twelve months
- $86M
- Net income, trailing twelve months
- −$177M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- −6.7%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Drug Manufacturers, Specialty & Generic
Ranks #31 of 41 by RyuScore